特朗普要求大型藥廠大降美國藥價 禮來(LLY.US)股價轉跌
美國總統特朗普日前向禮來(LLY.US)、諾和諾德(NVO.US)及輝瑞(PFE.US)在內的全球17間大型製藥公司發信,要求將美國新藥價格削減至與部分外國市場相同或更低水平。
特朗普又指,美國政府願協助製藥公司在海外提高售價,以換取在美國市場降價,但附帶條件是所有因海外價格上調所得的額外收益,必須匯回美國,從而用作抵消本地的藥物開支。
消息公佈後,禮來股價轉跌,一度下跌0.7%;AbbVie(ABBV.US)回吐早前升幅。市場普遍關注特朗普此舉將對藥業巨頭的利潤結構及全球定價策略構成壓力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.